Background/aim To evaluate the safety and efficacy of ruthenium-106 (Ru-106) plaque brachytherapy in managing invasive ocular surface squamous neoplasia (OSSN). Methods This is a retrospective, non-comparative, interventional case series of 42 eyes with OSSN with histopathologically-proven corneal stromal and/or scleral invasion that underwent Ru-106 plaque brachytherapy. Main outcome measures were tumour regression, eye salvage, final visual acuity, treatment complications and metastasis. Results At presentation, the mean tumour basal diameter was 9.3 mm (range 5–26 mm) and thickness 3.1 mm (range 1.5–11 mm). Prior treatment included excision biopsy in two patients (5%), incision biopsy and topical interferon in one each (2%). Following excision with 4 mm clinically clear margins, corneal stromal and/or scleral invasion of OSSN was confirmed in all 42 cases, with the excised base showing invasive squamous cell carcinoma. A total dose of 5000 cGy over a mean duration of 19.7 hours (range 7–41 hours) was provided to an axial depth of 2 mm using Ru-106 surface plaque. Over a mean follow-up of 36.9 months (range 22.3–72 months), complete tumour regression was achieved in all eyes (100%). Two eyes (5%) showed conjunctival tumour growth remote from the site of prior treatment. Visual acuity was maintained at ≥20/200 in 35 eyes (83%), with a loss of >2 Snellen lines in 1 eye (2%). There was no evidence of regional lymph node or systemic metastasis. Conclusion Histopathology-guided use of Ru-106 surface plaque brachytherapy is a safe and an effective adjuvant therapy in the management of corneal stromal and/or scleral invasion of OSSN. All data relevant to the study are included in the article or uploaded as online supplemental information. NA.

中文翻译：

---

使用钌 106 斑块近距离放射治疗在组织病理学指导下治疗伴有角膜基质或巩膜浸润的眼表鳞状瘤

背景/目的 评估 106 钌 (Ru-106) 斑块近距离放射治疗治疗浸润性眼表鳞状肿瘤 (OSSN) 的安全性和有效性。方法 这是一项回顾性、非比较性、介入性病例系列，包括 42 只经组织病理学证实有角膜基质和/或巩膜浸润并接受 Ru-106 斑块近距离放射治疗的 OSSN 眼。主要结果指标是肿瘤消退、眼睛挽救、最终视力、治疗并发症和转移。结果 就诊时，平均肿瘤基底直径为 9.3 毫米（范围 5-26 毫米），厚度为 3.1 毫米（范围 1.5-11 毫米）。既往治疗包括 2 名患者 (5%) 的切除活检、各 1 名 (2%) 患者的切开活检和局部干扰素。以 4 mm 临床清晰边缘切除后，所有 42 例均证实 OSSN 的角膜基质和/或巩膜浸润，切除基底部显示浸润性鳞状细胞癌。使用 Ru-106 表面斑块，在 19.7 小时（范围 7-41 小时）的平均持续时间内提供 5000 cGy 的总剂量至 2 mm 的轴向深度。在平均 36.9 个月（范围 22.3-72 个月）的随访中，所有眼睛 (100%) 均实现了肿瘤完全消退。两只眼睛 (5%) 显示远离先前治疗部位的结膜肿瘤生长。35 只眼 (83%) 的视力保持在 ≥20/200，1 只眼 (2%) 的视力丧失 >2 条斯内伦线。没有区域淋巴结或全身转移的证据。结论 在组织病理学指导下使用 Ru-106 表面斑块近距离放射治疗是治疗 OSSN 角膜基质和/或巩膜浸润的一种安全有效的辅助疗法。与研究相关的所有数据都包含在文章中或作为在线补充信息上传。不适用。